

1 **Pathway-based polygenic score analysis identifies the NRF2-**  
2 **KEAP1 and mRNA splicing - minor pathways as enriched in**  
3 **shared genetic variation between chronotype and bipolar disorder.**

4  
5  
6 Laura Fahey<sup>1</sup>, Lorna M. Lopez<sup>1</sup>

7  
8  
9 <sup>1</sup> Department of Biology, Maynooth University, Maynooth, Co. Kildare, Ireland

10  
11  
12 **Author Summary**

13 This study investigates shared genetic influences that may contribute to the circadian rhythm disruption  
14 and sleep issues in neurodevelopmental and neuropsychiatric conditions. Using polygenic score  
15 analysis on large-scale genetic studies of autism, attention-deficit/hyperactivity disorder, schizophrenia,  
16 and bipolar disorder, we tested their ability to predict chronotype and insomnia status of participants in  
17 the UK Biobank. Our findings reveal that polygenic scores for autism, schizophrenia, and bipolar  
18 disorder are associated with an evening chronotype, while polygenic scores for attention-  
19 deficit/hyperactivity disorder, autism, schizophrenia, and bipolar disorder are associated with insomnia.  
20 Pathway analysis identified the enrichment of shared genetic variation between chronotype and bipolar  
21 disorder in the NRF2-KEAP1 and mRNA splicing minor pathways. Previous studies have linked the  
22 NRF2-KEAP1 pathway to the pathology of bipolar disorder and schizophrenia. NRF2 and splicing  
23 components have been previously reported to be rhythmically regulated by circadian clock genes. These  
24 results suggest a potential role for the NRF2-KEAP1 and mRNA splicing minor pathways in mediating  
25 circadian rhythm disturbances in bipolar disorder, providing insights into the genetic basis of sleep  
26 issues in neuropsychiatric conditions.

27  
28  
29 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

## 30 Abstract

31 It has been postulated that circadian dysfunction may contribute to the sleep problems prevalent in  
32 neurodevelopmental and neuropsychiatric conditions. Genetic correlations between numerous pairs of  
33 neurodevelopmental or neuropsychiatric and sleep phenotypes have been identified. We hypothesize  
34 that this overlapping genetic variation is enriched in certain biological pathways.

35 We used genome-wide polygenic score analysis to confirm previously reported genetic correlations and  
36 pathway-based polygenic score analysis to identify enriched pathways. We created polygenic scores  
37 using summary statistics from the largest genome-wide association studies (GWAS) of autism (AUT),  
38 attention-deficit/hyperactivity disorder (ADHD), schizophrenia (SCZ) and bipolar disorder (BP). We  
39 tested the performance of these polygenic scores in predicting chronotype and insomnia status of UK  
40 Biobank participants. For the pathway-based polygenic scores, we restricted genetic variation to SNPs  
41 that mapped to genes within 451 pathways from the Reactome database.

42 Genome-wide polygenic scores for AUT, SCZ and BP were found to be associated with an evening  
43 chronotype, and polygenic scores for ADHD, AUT, SCZ and BP were found to be associated with  
44 insomnia status. Pathway-based polygenic score analysis identified the *NRF2 KEAP1* and *mRNA*  
45 *splicing minor* pathways as being enriched for genetic variation overlapping between chronotype and  
46 BP. For the *NRF2 KEAP1* pathway, the signal is enriched in the subset of genes that function with  
47 KEAP1 to regulate *NRF2* expression. Examination of eQTL data pointed to BP associated SNPs within  
48 these gene-sets being associated with expression changes of many genes to which they map. A number  
49 of these eQTL SNPs were reported to be genome-wide significant for SCZ in previous studies.

50 These results demonstrate that the overlapping genetic variation between chronotype and BP is enriched  
51 in genes involved in the *NRF2-KEAP1* and *mRNA splicing minor* pathways. Animal model and human  
52 cell line studies have previously linked the NRF2 pathway to the pathology of BP and SCZ.  
53 Additionally, NRF2 and splicing components have been reported to be rhythmically regulated by  
54 circadian clock genes. Our results suggest that these pathways could be involved in mediating the  
55 disrupted circadian rhythm phenotype of BP.

56

57

58

59

## 60 **Introduction**

61 Neurodevelopmental and neuropsychiatric conditions (NDPCs) encompass conditions that affect brain  
62 function, cognitive-processes, emotions and behaviour. Neurodevelopmental conditions manifest in  
63 childhood, with the most prevalent ones including autism spectrum disorder (AUT) and attention deficit  
64 hyperactivity disorder (ADHD) (1). Neuropsychiatric conditions typically have onset in adulthood and  
65 include schizophrenia (SCZ) and bipolar disorder (BP). NDPCs are characterised by their  
66 symptomatology, with many of them displaying overlapping symptoms. One example of such  
67 overlapping symptoms are sleep problems, considered a core symptom in the diagnostic criteria for BP  
68 (DSM-5; American Psychiatric Association, 2013), present in up to 80% of individuals with SCZ (3)  
69 and AUT (4,5) and observed in up to 50% of those with ADHD (6).

70 Sleep is regulated by sleep/wake homeostasis, which balances the urge to sleep and the requirement for  
71 wakefulness. As wakefulness persists, the homeostatic sleep drive intensifies, promoting sleep. Sleep  
72 is also regulated by the circadian clock, a biological timing mechanism that is controlled by 24-hour  
73 transcription-translational feedback loops involving several core clock genes. The central circadian  
74 pacemaker in the suprachiasmatic nucleus (SCN) of the hypothalamus responds to external cues, such  
75 as light signals, and synchronizes circadian rhythms across all cells in the body (7).

76 Both sleep/wake homeostasis and circadian rhythm have been shown to be disrupted in NDPCs.  
77 Disruption of homeostatic sleep drive, as indicated by reduced slow-wave activity, has been reported in  
78 SCZ and early-stage psychosis (8,9). Melatonin and cortisol are two hormones involved in circadian  
79 regulation. Melatonin is produced at night, while cortisol is primarily produced in the morning (10).  
80 Dysregulation of both hormones has been observed in NDPCs. For example, AUT has been associated  
81 with lower levels of melatonin at night (10,11) and ADHD has been associated with lower levels of  
82 cortisol after waking (12). Significant reductions in melatonin levels have also been reported in the  
83 cerebrospinal fluid of BP patients (13). Conversely, activities that disrupt circadian rhythms, such as  
84 shift work and frequent transatlantic flights, have been associated with adverse mental health (14).  
85 Hence, a bidirectional relationship appears to exist, where environmental disruptions to circadian  
86 rhythm exacerbate NDPC symptoms, while inherent circadian rhythm disturbances potentially  
87 contribute to the development of NDPCs or share underlying mechanisms. This supports the hypothesis  
88 that overlapping genetic variation contributes to both circadian disruption and the development of  
89 NDPCs. Indeed, mouse models with circadian clock gene mutations display symptoms reminiscent of  
90 human NDPCs, with different gene or protein domain mutations resulting in varying sets of NDPC  
91 symptoms (15).

92 Genome-wide association studies (GWASs) have identified hundreds of genome-wide single nucleotide  
93 polymorphisms (SNPs) associated with different NDPCs and sleep related phenotypes. Chronotype  
94 refers to individual's preference for wakening and performing activity earlier in the day (morning

95 chronotype) or later (evening chronotype). It is a behavioural manifestation of an individual's circadian  
96 clock and is often used as a proxy phenotype for circadian timing (16). In modern society, having a  
97 morning chronotype is considered advantageous due to its alignment with early school and work start  
98 times. Consequently, individuals with an evening chronotype may experience reduced sleep on  
99 work/school days and compensate for it on free days - this is known as 'social jetlag' (17). Evening  
100 chronotypes have been associated with numerous adverse psychological outcomes (18). The most  
101 recent GWAS of a morning chronotype reported enrichment of chronotype associated loci in the clock  
102 genes *PER1*, *PER2*, *PER3*, *CRY1* and *BMAL1*. Furthermore, the top enriched biological pathways relate  
103 to the circadian clock (19).


104 Surprisingly, no core clock genes have been linked with any NDPC through large-scale GWAS.  
105 However, genome-wide correlations in GWAS identified SNP effects have been reported between  
106 many sleep traits and NDPCs using the linkage disequilibrium score regression tool (Figure 1). This  
107 relationship is negative for the advantageous morning chronotype and positive for insomnia and  
108 daytime sleepiness, which are both debilitating. Polygenic score (PGS) analysis can also be used to  
109 assess genetic correlations between phenotypes. If a PGS created using effect sizes from a GWAS of  
110 one phenotype can significantly predict the phenotype of samples in an independent cohort, it indicates  
111 shared genetic variation between the two phenotypes in question (20). PGSs for ADHD and depression  
112 have been reported to positively correlate with initiating and maintaining sleep and excessive  
113 somnolence in children. Additionally, a PGS for anxiety disorder correlated with nightmares in children  
114 (21). These genetic correlation findings suggest that the shared genetic background between NDPCs  
115 and circadian rhythms likely extends genome-wide, beyond the core clock genes.

116 Exploring the genes, biological pathways and tissue types impacted by the shared genetic variation  
117 between sleep and NDPCs has been a relatively unexplored area. A gene-based cross-trait meta-analysis  
118 identified forty-four genes common to both insomnia and ADHD, and found them to be enriched for  
119 genes within synaptic-related pathways (22). Another study identified 149 loci shared between  
120 psychiatric disorders (SCZ, BP and depression) and sleep traits (chronotype and sleep duration). Forty-  
121 nine lead SNPs at these loci were found to act as eQTLs for 115 genes across various brain tissues  
122 including the basal ganglia, cortex, hippocampus and cerebellum (23).

123 The aims of this study were two-fold. First, we investigated if genome-wide polygenic scores for  
124 ADHD, AUT, SCZ and BP could predict insomnia and chronotype in UKB. Secondly, using pathway-  
125 based polygenic score analysis, we investigated the biological pathways implicated by shared genetic  
126 variation between these NDPC and sleep phenotypes. We report that polygenic scores for AUT, SCZ  
127 and BP were associated with chronotype status and polygenic scores for all four NDPC phenotypes  
128 were associated with insomnia. BP polygenic scores, restricted to genetic variation in the *KEAPI-NRF2*  
129 and *mRNA splicing-minor* biological pathways were both significant in predicting chronotype, over and

130 above the background signal. To gain further biological insights, we reviewed expression quantitative  
131 trait loci data, and found many BP associated SNPs within these gene sets to be associated with  
132 expression changes of the genes to which they map.

133



134

135 **Figure 1. Published genetic correlations ( $r_g$ ) between pairs of neuropsychiatric or**  
136 **neurodevelopmental and sleep phenotypes.** Heatmap cells marked with an asterisk (\*) indicate that  
137 they were reported as statistically significant in the original publications, after multiple testing  
138 correction. The original publications include the latest and largest genome-wide association studies of  
139 Autism (AUT; Grove et al., 2019), morning chronotype (Jones et al., 2019), attention-deficit  
140 hyperactivity disorder (ADHD; Demontis et al., 2023), bipolar disorder (BP; Mullins et al., 2021), major  
141 depressive disorder (MDD; Howard et al., 2019), sleep duration (Dashti et al., 2019) and daytime  
142 sleepiness (Wang et al., 2019). Rows and columns are clustered based on similarity.

## 143 Results

### 144 Genome-wide polygenic score analysis

145 To test for indication of shared genetic variation, we investigated if genome-wide polygenic scores for  
146 AUT, ADHD, SCZ and BP could predict chronotype and/or insomnia status of UKB participants. We  
147 implemented this using the PGS tool, SBayesRC, which re-estimates GWAS SNP effect sizes using a  
148 model that incorporates external linkage disequilibrium (LD) and biological annotation data (24). As  
149 discovery data for PGS analysis, we used publicly available GWAS summary statistics for the NDPC

150 phenotypes, which were based on studies containing between 46,350 (AUT) and 225,534 (ADHD)  
151 samples. As target data for PGS analysis, we used UKB genotype and questionnaire data related to  
152 chronotype and insomnia. After quality control, we had 409,630 samples with chronotype data and  
153 239,918 samples with insomnia data (see methods).

154 Polygenic scores for AUT, SCZ and BP, were statistically significant for association with chronotype  
155 status (AUT:  $r^2 = 3.57 \times 10^{-4}$  [95% CI =  $2.51 \times 10^{-4}$  -  $4.82 \times 10^{-4}$ ],  $p = < 2.20 \times 10^{-16}$ ; SCZ:  $r^2 = 5.13 \times 10^{-4}$  [95%  
156 CI =  $3.84 \times 10^{-4}$  -  $6.61 \times 10^{-4}$ ],  $p = < 2.20 \times 10^{-16}$ ; BP:  $r^2 = 2.97 \times 10^{-5}$  [95% CI =  $5.71 \times 10^{-6}$  -  $7.25 \times 10^{-5}$ ],  $p =$   
157  $4.84 \times 10^{-4}$ ) (Figure 2, Supplementary Table 1). Polygenic scores for all four GWAS phenotypes were  
158 statistically significant for association with insomnia, the strongest association being between the  
159 ADHD PGS and insomnia (ADHD:  $r^2 = 2.36 \times 10^{-3}$  [95% CI =  $1.99 \times 10^{-3}$  -  $2.76 \times 10^{-3}$ ],  $p = < 2.20 \times 10^{-16}$ ;  
160 AUT:  $r^2 = 3.69 \times 10^{-5}$  [95% CI =  $4.29 \times 10^{-6}$  -  $1.02 \times 10^{-4}$ ],  $p = 2.93 \times 10^{-3}$ ; BP:  $r^2 = 1.10 \times 10^{-4}$  [95% CI =  
161  $4.19 \times 10^{-5}$  -  $2.09 \times 10^{-4}$ ],  $p = 2.90 \times 10^{-7}$ ; SCZ:  $r^2 = 3.32 \times 10^{-5}$  [95% CI =  $3.07 \times 10^{-6}$  -  $9.52 \times 10^{-6}$ ],  $p = 4.79 \times 10^{-$   
162  $3$ ; Figure 2; Supplementary Table 1). To enable direct comparison to the pathway PGS analysis in the  
163 next section, we also report genome-wide PGSs calculated using the tool, PRSice-2 (Choi & O'Reilly,  
164 2019), with a P-value threshold of 0.5 (Supplementary Table 1). These results are very similar to those  
165 obtained with SBayesRC, with the exception that SBayesRC performed better in the prediction of an  
166 evening chronotype based on all four NDPC PGSs, and also performed better in the prediction of  
167 insomnia based on the ADHD PGS. This improvement is to be expected given that the calculation of  
168 PGSs using LD clumping and p-value thresholding, as in PRSice-2, is not the optimal method for  
169 genome-wide PGS analysis (26).

## 170 **Pathway-based polygenic score analysis**

171 Pathway-based polygenic score analysis was performed to test if shared genetic variation exists between  
172 AUT, ADHD, SCZ or BP and chronotype or insomnia status at the biological pathway level. Here, all  
173 eight pairs of phenotypes were tested, regardless of whether statistically significant results were  
174 observed at the genome-wide level, because it is possible that shared genetic effects are present in  
175 certain biological pathways, but the effects are too small to be observable at a genome-wide level. We  
176 tested all Reactome pathways that contained between 50 and 500 genes, resulting in 451 pathways to  
177 test. Pathway-based polygenic scores were derived using SNPs that map by position to each of the 451  
178 pathways.

179 Two pathways were statistically significant for the prediction of chronotype status based on BP genetic  
180 variation. These pathways encompass the *mRNA splicing - minor pathway* ( $r^2 = 7.5 \times 10^{-5}$  [95% CI =  
181  $3.13 \times 10^{-5}$  -  $1.26 \times 10^{-4}$ ],  $P = 3.18 \times 10^{-8}$ , competitive  $P = 1.33 \times 10^{-5}$ ) and the *KEAP1 NRF2 pathway* ( $r^2 =$   
182  $7.18 \times 10^{-5}$  [95% CI =  $2.92 \times 10^{-5}$  -  $1.33 \times 10^{-3}$ ],  $P = 6.26 \times 10^{-8}$ , competitive  $P = 1.33 \times 10^{-5}$ ; Figure 3,  
183 Supplementary Table 2). Note that the competitive P value achieved for each of these significant gene-  
184 sets was the lowest possible based on the 75,000 permutations performed. Interestingly, the *mRNA*

185 *splicing - minor* pathway also ranked the highest, in terms of competitive P value, for the prediction of  
186 chronotype based on the SCZ PGS, but this did not surpass the multiple testing corrected threshold ( $r^2$   
187 =  $5.62 \times 10^{-5}$  [95% CI =  $1.96 \times 10^{-5}$ - $1.12 \times 10^{-4}$ ],  $P = 1.65 \times 10^{-6}$ , competitive  $P = 1.0 \times 10^{-3}$ ; Supplementary  
188 Table 2).

189 No pathway PGS achieved a competitive P value that passed multiple testing correction for the  
190 prediction of insomnia. The pathway *Nuclear Events Mediated by NRF2*, which is a subpathway of  
191 *KEAPI NRF2*, ranked as the second and third highest performing pathways, out of all 451 tested, for  
192 the prediction of insomnia based on SCZ and BP PGSs, respectively (Figure 3, Supplementary Table  
193 3). Competitive P values for the top four pathway PGSs for each of the eight phenotype pairs are  
194 visualised as a heatmap in Figure 3.

## 195 **Post-hoc analyses**

### 196 **Interrogations of significant pathway-based polygenic score analysis results**

197 The *mRNA Splicing – Minor Pathway* encompasses 50 genes, to which 518 SNPs map, while the  
198 *KEAPI NRF2* pathway comprises 107 genes, to which 1,356 SNPs map. To explore potential  
199 enrichment of the observed signal within specific subsets of these pathways, we investigated Reactome  
200 subpathways, some of which were initially omitted due to our criteria of excluding pathways with fewer  
201 than 50 genes. Given the relatively small size of the *mRNA splicing – minor pathway*, it does not contain  
202 any Reactome subpathways. In contrast, the *KEAPI NRF2* pathway could be broken down into two  
203 Reactome subpathways, and an additional pathway that we established comprising of all genes that do  
204 not fall into these two subpathways, which we referred to as *Regulation of NRF2 by KEAPI*. Among  
205 the *KEAPI NRF2* sub-pathways, the gene-set that explained the most variance was *Regulation of NRF2*  
206 *by KEAPI* ( $R^2 = 5.0 \times 10^{-5}$  [95% CI =  $1.6 \times 10^{-5}$ - $1.03 \times 10^{-4}$ ],  $P = 6.25 \times 10^{-6}$ , competitive  $P = 1.87 \times 10^{-4}$ ;  
207 Figure 4a; Supplementary Table 4). To account for the size of the pathways, we plotted the average  
208 variance in chronotype explained per SNP for these pathway PGSs, in comparison to the average  
209 variance explained per SNP by a PGS constructed using SNPs that map to all HGNC gene symbols  
210 (Figure 4b; Supplementary Tables 2 and 4).

### 211 **eQTL Analysis Results**

212 To gain a better understanding of the effect of BP genetic variation on the expression of genes within  
213 the *mRNA Splicing – Minor Pathway* and *KEAPI NRF2* pathways, we reviewed expression quantitative  
214 trait loci (eQTLs) data in the database, QTLBase (27). For the *KEAPI NRF2* pathway, five genes  
215 satisfied the criteria of having gene P values  $< 1 \times 10^{-2}$  for BP and  $< 1 \times 10^{-3}$  for chronotype based on gene-  
216 based MAGMA analysis. Of these genes, three contained BP SNPs associated with their expression  
217 change: *cullin-3 (CUL3)*, *proteasome 26S subunit ubiquitin receptor, non-ATPase 2 (PSMD2)* and  
218 *proteasome 20S subunit beta 10 (PSMB10)*.

219 CUL3 is a core component of the CUL3-dependent E3 ubiquitin ligase complex which mediates  
220 ubiquitination and subsequent degradation of target proteins. This complex associates with KEAP1 to  
221 ubiquitinate NRF2, maintaining its abundance at a low level (28) At *CUL3*, the BP allele of the most  
222 significant BP SNP (rs6748341) is associated with decreased expression of *CUL3* in the brain cortex ( $P$   
223 =  $4.91 \times 10^{-6}$ ). Interestingly, a SNP in very high (LD) with this SNP (rs11685299; LD  $R^2 = 0.99$ ) is  
224 genome-wide significant for association with SCZ (29). The BP allele of a SNP in high LD with both  
225 of these SNPs (rs11681451) is also associated with decreased expression of *CUL3*, this time in three  
226 brain regions (Cortex  $P = 1.81 \times 10^{-6}$ , Hippocampus  $P = 1.95 \times 10^{-5}$ , Caudate  $P = 2.33 \times 10^{-5}$ ; Supplementary  
227 Table 5).

228 The gene *PSMD2* encodes a subunit of the 26S proteasome, which degrades NRF2 (28). At *PSMD2*,  
229 the BP allele of rs843355 is associated with decreased expression of *PSMD2* in various immune cells  
230 in the blood, including Blood-Neutrophils CD16+ ( $P = 1.38 \times 10^{-6}$ ) and Blood-Monocytes ( $P = 1.79 \times 10^{-6}$ )  
231 (Supplementary Table 5).

232 Similarly to *PSMD2*, the *PSMB10* gene also encodes a proteasomal subunit involved in NRF2  
233 degradation (28). At *PSMB10*, the BP allele of rs5923 is associated with both increased and decreased  
234 expression of *PSMB10* in various blood immune cells (Increased: Blood  $P = 4.2 \times 10^{-9}$ , Blood-Monocytes  
235 CD14+  $P = 5.11 \times 10^{-9}$ , Blood-Neutrophils CD16+  $P = 2.94 \times 10^{-7}$ ; Decreased: Blood-Monocytes CD14+  
236  $P = 9.56 \times 10^{-7}$ , Blood-Neutrophils CD16+  $P = 8.21 \times 10^{-6}$ ).

237 For the *mRNA Splicing - Minor Pathway*, six genes satisfied the criteria of having gene  $P$  values  $< 1 \times 10^{-2}$   
238 for BP and  $< 1 \times 10^{-3}$  for chronotype: *splicing factor 3b subunit 1 (SF3B1)*, *splicing factor 3b subunit 1*  
239 (*SF3B2*), *RNA polymerase II, I And III subunit H (POLR2H)*, *small nuclear ribonucleoprotein U5*  
240 *Subunit 200 (SNRNP200)* and *pre-mRNA processing factor 6 (PRPF6)*.

241 *SF3B1* encodes subunit 1 of the splicing factor 3b protein complex (SF3b) which is a component of the  
242 U12 small nuclear ribonucleoprotein (snRNP) of the minor spliceosome and a component of the U2  
243 snRNP of the major spliceosome. At *SF3B1*, the BP allele of the SNP most associated with BP  
244 (rs55775495) is associated with increased expression of SF3B in the central nervous system ( $P =$   
245  $2.68 \times 10^{-15}$ ), peripheral nervous system ( $P = 1.13 \times 10^{-6}$ ), brain cerebellum ( $P = 1.30 \times 10^{-6}$ ) and brain  
246 caudate ( $P = 2.19 \times 10^{-6}$ ). Interestingly, the SNP rs6434928, which is in very high LD ( $R^2 = 0.88$ ) with  
247 this SNP is genome-wide significant for association with SCZ (30) and has almost the exact same eQTL  
248 results. *SF3B2* encodes subunit 2 of SF3b. The BP allele of rs2270448 is associated with decreased  
249 expression of *SF3B2* in the brain cerebellum ( $P = 1.28 \times 10^{-5}$ ).

250 *POLR2H* encodes a subunit shared by the three eukaryotic polymerases. The BP allele of rs62287507  
251 is associated with increased expression of POLR2H in blood ( $P = 2.33 \times 10^{-6}$ ). *SNRNP200* encodes an  
252 RNA helicase that comprises one of the U5 snRNP-specific proteins. At *SNRNP200*, the BP allele is  
253 associated with increased expression in blood neutrophils CD16+ ( $P = 2.02 \times 10^{-11}$ ). *PRPF6* encodes a



254 protein that acts as a bridging factor between U5 and U4/U6 snRNPs in formation of the spliceosome.  
255 The encoded protein can also bind androgen receptor, providing a link between transcriptional  
256 activation and splicing. The BP allele of the most significant SNP at this loci, rs3829704, is associated  
257 with decreased expression of PRPF6 in blood cells (Lymphocyte  $P = 1.29 \times 10^{-31}$ , Blood  $P = 3.95 \times 10^{-11}$ ,  
258 Blood-T cell CD4+ activated  $P = 1.48 \times 10^{-7}$ ) and decreased expression of PRPF6 in the brain (Cortex  $P$   
259  $= 1.2 \times 10^{-6}$ ; Caudate,  $P = 6.0 \times 10^{-6}$ ).

## 260 Differential Expression Analysis

261 We next investigated if genes within the *mRNA Splicing – Minor Pathway* and *KEAP1 NRF2* pathway  
262 are differentially expressed between BP cases and controls. We used PsychEncode differential  
263 expression data based on postmortem dorsolateral prefrontal cortex samples from 144 BP cases and 899  
264 healthy controls. Two genes within the mRNA Splicing – Minor Pathway were found to be differentially  
265 expressed. These are *Serine and Arginine Rich Splicing Factor 6* (*SRSF6*;  $\log_2FC = -0.07$ ;  $P = 2.0 \times 10^{-4}$ ;  
266  $FDR = 0.01$ ) and *Small Nuclear Ribonucleoprotein Polypeptides B and B1* (*SNRPB*;  $\log_2FC = 0.08$ ;  
267  $P = 4.4 \times 10^{-4}$ ;  $FDR = 0.02$ ). Four differentially expressed genes were observed in the *KEAP1 NRF2*  
268 pathway. These are *Sestrin 1* (*SESN1*;  $\log_2FC = 0.07$ ;  $P = 2.8 \times 10^{-4}$ ;  $FDR = 0.02$ ), *cyclin dependent*  
269 *kinase inhibitor 1A* (*CDKN1A*  $\log_2FC = 0.32$ ;  $P = 2.51 \times 10^{-4}$ ;  $FDR = 0.02$ ), *AKT serine/threonine kinase*  
270 *1* (*AKT1*;  $\log_2FC = 0.04$ ;  $P = 6.8 \times 10^{-4}$ ;  $FDR = 0.03$ ) and *MAF BZIP Transcription Factor G* (*MAFG*;  
271  $\log_2FC = -0.05$ ;  $P = 4.9 \times 10^{-4}$ ;  $FDR = 0.02$ ). Interestingly, three of these genes are present in *Regulation*  
272 *of NRF2 by KEAP1*, which had a higher average  $R^2$  per SNP than the *KEAP1 NRF2* pathway itself  
273 (Figure 4b). However, none of these gene-sets had a statistically significant enrichment of differentially  
274 expressed genes (*Regulation of NRF2 by KEAP1*  $P = 0.09$ ; *KEAP1 NRF2*  $P = 0.5$ ; *mRNA Splicing –*  
275 *Minor Pathway*  $P = 0.5$ ).

276

## 277 Discussion

278 Using genome-wide polygenic score analysis, we have found that polygenic scores for AUT, SCZ and  
279 BP could predict an evening chronotype and polygenic scores for all four NDPC phenotypes could  
280 predict insomnia status in UKB. Pathway-based polygenic score analysis identified the *NRF2 KEAP1*  
281 and *mRNA splicing minor* pathways as being enriched for genetic variation overlapping between  
282 chronotype and BP. For the *NRF2 KEAP1* pathway, the signal is enriched in the subset of genes that  
283 function with KEAP1 to regulate *NRF2* expression. Examination of eQTL data pointed to BP associated  
284 SNPs being associated with expression changes of many genes within the highlighted pathways to  
285 which they map. Interestingly, three of the ten eQTL SNPs are genome-wide significant for SCZ  
286 (Supplementary Table 5).

287 The genome-wide polygenic score results we report support previously published genetic correlation  
288 results. AUT and SCZ have previously been reported to exhibit a negative genetic correlation with a  
289 morning chronotype, as demonstrated by linkage disequilibrium score regression (31,32). Using a  
290 different method and data, our study provides further evidence for these findings, as well as  
291 demonstrating a positive association between the BP PGS and an evening chronotype. Additionally, our  
292 results confirm that insomnia is genetically correlated with ADHD, SCZ and BP (33–35), the strongest  
293 relationship being between ADHD and insomnia. We also report a negative genetic correlation between  
294 AUT and insomnia, whereas, in previous studies this relationship was not statistically significant (31).

295 BP polygenic scores created using SNPs that map to the *KEAPI NRF2* and *mRNA splicing-minor*  
296 Reactome pathways were associated with chronotype, over and above the background signal. The  
297 majority of the variance explained by the *KEAPI NRF2* gene-set is concentrated within genes belonging  
298 to the subpathway, *Regulation of NRF2 by KEAPI*. It must be noted that the  $R^2$  values of these pathway-  
299 based PGSs are low. This is partly to be expected, given the small numbers of genes in these pathways.  
300 Clear enrichment of explained variance by the *mRNA splicing – minor* and *KEAPI NRF2* pathways are  
301 observed when plotting the average variance explained per SNP for these pathways in comparison to  
302 the average variance explained per SNP by PGSs created using all genes based on BP genetic variation  
303 (Figure 4b).

304 A sub-pathway of *KEAPI-NRF2*, *Nuclear Events Mediated by NRF2*, ranked very highly in predicting  
305 insomnia status, based on BP and SCZ genetic variation. This did not reach statistical significance,  
306 possibly due there being less insomnia samples (N=239,918) than chronotype samples (N=409,630),  
307 and therefore reduced power. NRF2 is a transcription factor that, under normal conditions, is bound by  
308 KEAP1 in the cytoplasm as part of the CUL3-KEAP1 E3 ubiquitin ligase complex, which facilitates  
309 the ubiquitination of NRF2, marking it for proteasomal degradation. When cells are exposed to  
310 oxidative stress, toxins, bacteria, viruses or other forms of cellular damage, KEAP1 cysteine residues  
311 are modified, disrupting its binding affinity for NRF2. As a result, NRF2 stabilises and translocates to  
312 the nucleus where it binds antioxidant response elements (AREs) in the promoter regions of genes  
313 encoding antioxidant enzymes and detoxification proteins (36). Of particular interest regarding sleep  
314 and circadian rhythms, NRF2 has also been observed to undergo rhythmic regulation by the two  
315 circadian clock genes, *BMAL1* and *CLOCK*, in myeloid cells. These clock genes promote *NRF2*  
316 expression by binding to the NRF2 E-box domain (37). Through these pathways, NRF2 mediates  
317 coupling between oscillations in redox balance and circadian timekeeping mechanisms, with this loop  
318 serving to optimise the timing of circadian and seasonal timing of antioxidant responses (38,39).

319 Elevated oxidative stress has been consistently documented in numerous NDPCs (including BP), and  
320 this contributes to the concurrent neuroinflammation observed in these conditions (40,41). The  
321 increased expression of NRF2 target genes help cells mitigate oxidative stress, improve mitochondrial

322 function and reduce inflammation, all of which are involved in the pathology of NDPCs (36,42). NRF2  
323 also acts as a negative regulator of the NF $\kappa$ B signalling pathway, while the NF $\kappa$ B pathway reciprocally  
324 negatively regulates NRF2 signalling. This interaction helps maintain control over basal inflammation  
325 and oxidative stress levels (43). When the NRF2 pathway becomes saturated or is deficient, activation  
326 of the NF $\kappa$ B pathway is heightened, which leads to an increased production of pro-inflammatory  
327 cytokines (36). Given this relationship, it is therefore interesting that the *KEAP1 NRF2* and *Nuclear*  
328 *Events Mediated by NRF2* pathways clustered together with the *FCERI mediated NF- $\kappa$ B activation*  
329 pathway competitive P value heatmap of the top four pathways across all phenotype pairs (Figure 3).

330 Studies in a seasonal animal model (Meduka fish) that exhibits a constitutive depressive winter  
331 phenotype have shown that NRF2 signalling pathways were inactivated in winter photoperiods, and  
332 that this was associated with a depressive phenotype that could be reversed by treatment with NRF2  
333 activators (44). These functions of NRF2 signalling in regulating seasonal changes in behaviour are  
334 significant since seasonality is such an important clinical feature of human NDPCs. For example, the  
335 prevalence of major depressive disorder and seasonal affective disorder show seasonal variation and  
336 the oscillations in mood and metabolic function that characterise BP recur with a seasonal rhythm (45).  
337 Furthermore, people with BP have higher self-reported seasonality scores (46) and altered sensitivity to  
338 changes in day light (47). Chronotype also links seasonality and BP, as evening chronotype is associated  
339 with increased self-reported seasonality (48) and with the presence and severity of signs of BD (49).

340 Given the beneficial antioxidant and anti-inflammatory roles of NRF2, it may be hypothesized that  
341 NRF2 is downregulated in NDPCs. This was observed in animal models of depression, where lower  
342 levels of NRF2 and KEAP1 were reported in the prefrontal cortex and the dentate gyrus and Cornu  
343 Ammonis 3 (CA3) regions of the hippocampus, along with increased blood levels of inflammatory  
344 cytokines (50). Similar results were seen using human postmortem samples, where protein levels of  
345 KEAP1 and NRF2 in the parietal cortex of major depressive disorder, schizophrenia, and bipolar  
346 disorder samples were significantly lower than controls. Indeed, there is evidence supporting the  
347 potential of natural and synthetic molecules, including melatonin, that elevate NRF2 levels to be used  
348 as treatments for psychiatric conditions (36,42).

349 However, there is some disagreement in the literature, with some studies reporting that NRF2 signalling  
350 is upregulated in NDPCs. For example, Lukic et al. (2014) reported increased abundance of NRF2,  
351 KEAP1, and NF- $\kappa$ B within the cytoplasm of peripheral blood mononuclear cells of MDD patients (51).  
352 This lack of consistent direction, in terms of up- or down- regulation of NRF signalling, is reflected in  
353 our eQTL results, where BP genetic variation is associated with inconsistent changes in expression of  
354 genes within the NRF2 KEAP gene-set. For example, the *CUL3* gene encodes the cullin 3 protein,  
355 which is a core component of ubiquitin ligase complex which ubiquitinates NRF2 and the *PSMD2* gene  
356 encodes a subunit of a proteasome that degrades NRF2. Therefore, *CUL3* and *PSMD2* function together

357 to degrade NRF2, yet BP eQTLs within these genes are associated with expression changes that are in  
358 opposite directions. Additionally, the four genes within the NRF2 KEAP1 gene-set that are  
359 differentially expressed between BP cases and controls, based on PsychEncode differential expression  
360 data, are upregulated.

361 The other pathway highlighted by our study is the *mRNA-splicing minor pathway*. Splicing of mRNA  
362 refers to the removal of introns from pre-mRNA transcripts, a process performed by the spliceosome.  
363 The spliceosome comprises distinct complexes responsible for various mRNA splicing steps, composed  
364 of both proteins and small nuclear RNAs. While the majority of splicing events are carried out by the  
365 major spliceosome, a subset of introns, known as minor introns, necessitates the involvement of the  
366 minor spliceosome for their excision (52). Minor splicing is less efficient than major splicing, this  
367 reduced efficiency has been proposed to play a role in the regulation of genes containing minor introns,  
368 as minor intron containing transcripts are retained in the nucleus until the minor spliceosome  
369 components become available. Of relevance to NDPCs, the cerebral cortex is one of the tissues with  
370 the highest expression of genes containing minor introns (53).

371 The importance of minor intron splicing is evident by the fact that minor-intron containing genes are  
372 highly conserved and thirteen diseases have been linked to mutations in minor splicing components,  
373 including the neurodegenerative diseases, amyotrophic lateral sclerosis, and spinal muscular atrophy  
374 (52,54,55). A study by Buel and colleagues found oscillations in many components of the major  
375 spliceosome pathway mirror that of the *clock and bmal1* transcripts (56), indicating that the major  
376 spliceosomal pathway is at least partly regulated by the circadian clock. This is interesting in relation  
377 to the minor spliceosome too, given the overlap in these pathways. Interestingly, the biologically related  
378 pathway, *Processing of Capped Intron-Containing Pre-mRNA*, ranked as the second highest performing  
379 pathway PGS in the prediction of insomnia based on ADHD genetic variation. This pathway clustered  
380 together with *mRNA-splicing minor pathway* in the heatmap in Figure 3.

381 Neither the *NRF2 KEAP1* or the *mRNA-splicing minor* pathways were found to be enriched in genes  
382 differentially expressed between BP cases and controls in the *post-mortem* dorsolateral prefrontal  
383 cortex. It could be that these genes are differentially expressed in a different tissue type to the one we  
384 investigated or that the shared genetic variation we have identified only applies to a subset of  
385 individuals, and differential expression of these genes would only occur for this subset. A future analysis  
386 could select BP cases with high *NRF2 KEAP1 / mRNA-splicing minor* PGSs and restrict the differential  
387 analysis to just these cases (this would require genotype and RNA-sequencing data on BP cases and  
388 controls).

389 We implemented MAGMA gene-set analysis to investigate if the *NRF2 KEAP1* and *mRNA splicing*  
390 *minor* pathways could be identified using standard single phenotype pathway enrichment methods.  
391 Neither the *NRF2 KEAP1* and *mRNA splicing minor pathways* were enriched for genetic variation

392 individually associated with BP, chronotype or SCZ (Supplementary Table 6). This indicates that these  
393 pathways are enriched for the genetic variation shared between these two phenotypes and are not  
394 enriched for the genetic variation associated with each individual phenotype.

395 There are some limitations to the pathway-based PGS method we have implemented. Firstly, we  
396 mapped SNPs to genes solely based on the physical distance of SNPs to genes. While, it has been  
397 reported that the majority (76%) of GWAS SNPs affect the closest gene (57), SNPs can be located in  
398 regulatory elements up to hundreds of megabases away from the causal gene. Such distal causal genes  
399 were not included in our analysis. Another limitation is that polygenic score analysis cannot distinguish  
400 between horizontal versus vertical pleiotropy i.e. whether genetic variation within the *NRF2 KEAPI*  
401 and *mRNA splicing minor* pathways independently contribute to both BP and an evening chronotype,  
402 or whether genetic variation within these pathways contribute to an evening chronotype, which in turn,  
403 causes BP, or vice versa.

404 This is the first study to investigate the biological pathways enriched in genetic variation overlapping  
405 between NDPC and sleep phenotypes, using pathway-based PGS analysis in a global, rather than  
406 hypothesis-based design. We used the largest available datasets from GWASs of ADHD, AUT, BP as  
407 our discovery datasets, and our target dataset consisted of up to 409,630 samples from UKB.

408 Our findings of shared genetic variation between chronotype and BP in a pathway that is known to  
409 regulate circadian rhythms and seasonality in animals (*NRF2 KEAPI*) in addition to the strongly  
410 seasonal nature of the clinical features and prevalence of BP, are further evidence to support the  
411 hypothesis that disrupted circadian rhythm and seasonal adaptive responses underlie the pathology of  
412 BP (58). Furthermore, our findings highlight the *mRNA splicing-minor* pathway, which has also been  
413 shown to be at least partly regulated by the circadian clock. Thus, this study provides further evidence  
414 to support the circadian clock hypothesis of BP disorder.

415

## 416 **Methods**

### 417 **Target Data for Polygenic Score Analysis – UK Biobank**

#### 418 **Quality Control (QC)**

419 Genotype data was collected, processed and imputed by UKB (59). We accessed and analysed the data  
420 through the UKB Research Analysis Platform (Application ID: 71469). UKB research participants were  
421 excluded based on the following criteria: not being of Caucasian ancestry (data-field: 22006),  
422 containing a sex chromosomal aneuploidy (data-field: 22019), having a high SNP missingness and/or  
423 having unusually high or low heterozygosity (data-field: 22027), having ten or more third-degree  
424 relatives (data-field: 22021) and performing shift work (data-field: 826). Further samples were removed

425 based on relatedness using the UKB supplied relatedness file, which lists pairs of individuals related up  
426 to a third degree. One individual from each pair was removed without removing samples from pairs  
427 where a sample had already been removed. A total of 487,409 samples passed these quality control  
428 measures. To minimize any potential overlap between UKB and PGC SCZ and BP cohorts, participants  
429 who had received SCZ or BP diagnoses were excluded from the construction of the SCZ PGS or BP  
430 PGS, respectively. Such samples were identified through self-reported diagnoses (data-field: 20544)  
431 and linked health records reporting international classification of disease (ICD10) codes, F200-F209  
432 for SCZ and F310-F319 for BP (data-field: 41270). This resulted in a further removal of 1,223 SCZ  
433 samples and 1,866 BP samples, in the construction of the SCZ and BP PGSs, respectively.

434 SNPs were excluded based on the following criteria: imputation quality score (INFO) < 0.7, proportion  
435 of missing genotypes > 0.02, minor allele frequency (MAF) < 0.005, Hardy–Weinberg equilibrium  
436 (HWE) <  $1 \times 10^{-6}$ . Duplicate SNPs were removed using Plink2 with the flag “--rm-dup force-first”.  
437 Plink2 binary file-sets were created using the “--make-bed” flag and chromosome specific files were  
438 merged using the Plink2 “--merge-list” flag. Finally, ambiguous SNPs and SNPs not present in the  
439 corresponding neuropsychiatric GWAS were removed.

#### 440 **Phenotype Generation**

441 Two UKB phenotypes were used for this study: chronotype (“Morning/evening person (chronotype)”;  
442 data-field 1180) and insomnia (“sleeplessness/insomnia”; data-field 1200). These data points were  
443 gathered as part of a questionnaire participants completed on touchscreen computers at UKB assessment  
444 centres.

445 For chronotype, participants were asked the question, “do you consider yourself to be”?, and they had  
446 six optional answers, which we encoded as a quantitative eveningness phenotype: “Definitely an  
447 ‘evening’ person” was encoded as 4, “More an ‘evening’ than a ‘morning’ person” was encoded as 3,  
448 “More a ‘morning’ than an ‘evening’ person” was encoded as 2, “Definitely a ‘morning’ person” was  
449 encoded as 1, “Prefer not to answer” and “Do not know” were both encoded as missing. This resulted  
450 in 409,630 post-QC samples with chronotype data.

451 For insomnia, participants were asked the question, “do you consider yourself to be”? and had four  
452 optional answers, which we encoded in a binary fashion: “never/rarely” was encoded as 0, “usually”  
453 was encoded as 1 and “sometimes” and “Prefer not to answer” were both encoded as missing. This  
454 resulted in post-QC 239,918 samples with insomnia data.

#### 455 **Correcting for Confounders**

456 The UKB phenotypes were corrected for the effects of confounders by taking the residuals of regression  
457 models with the UKB phenotype as the dependent variable and the confounders as the independent  
458 variables. For the binary insomnia phenotype, a logistic regression model was used, while a linear

459 regression model was used for the quantitative chronotype phenotype. The residuals of these models,  
460 representing the variation in phenotype left unexplained by the effects of confounders, were assigned  
461 as the corrected phenotypes. The fourteen confounders corrected for were: age, sex, UKB assessment  
462 centre, genotyping batch and genetic principal components (PCs) 1-10.

### 463 **Discovery Data for Polygenic Score Analysis – GWAS Summary Statistics**

464 Discovery data for polygenic score analysis included summary statistics from the latest and largest  
465 published GWAS of AUT (18,381 cases and 27,969 controls from a Danish population (31)), ADHD  
466 (38,691 cases and 186,843 controls from European, Danish and Icelandic populations (33)), SCZ  
467 (74,776 cases and 101,023 controls from European, East Asian,  
468 African American and Latino populations (30)) and BP (41,917 cases and 31,358 controls from a  
469 European population (35)).

### 470 **Genome-Wide Polygenic Score Analysis**

471 Effect sizes for all imputed SNPs were estimated using SBayesRC based on GWAS summary statistics.  
472 SBayesRC models SNP effects using a mixture of normal distributions that differ in their variances and  
473 uses SNP annotation information to select which of these distributions best model SNP effect sizes.  
474 This allows for SNP effect probability distributions to differ across annotation groups and has been  
475 shown to perform better than other popular PGS methods (24). Inputs to SBayesRC include GWAS  
476 summary statistics, LD European reference data and data containing 96 functional annotations for 8  
477 million imputed SNPs (the latter two data files were downloaded from  
478 [github.com/zhilizheng/SBayesRC](https://github.com/zhilizheng/SBayesRC))

479 The first step involves converting GWAS summary statistics to COJO format, and converting odds  
480 ratios to beta values using  $\log(\text{OR})$  when beta values were not provided. Subsequently, the SBayesRC  
481 tidy function was run to filter SNPs based on inconsistent alleles between the GWAS summary statistic  
482 and LD data and per SNP sample sizes less than three standard deviations of the mean. The SBayesRC  
483 impute function was implemented to impute the GWAS summary data based on LD. This resulted in  
484 7,356,519 SNPs for each phenotype. The main SBayesRC function was then run to estimate SNP  
485 effects. These SNP effects were provided to the --score command in Plink1.9 to calculate PGSs for all  
486 individuals in the UKB test dataset (60). Performance metrics were calculated in R by running linear  
487 regressions with UKB chronotype or insomnia status as the dependent variable and the SCZ, BP, AUT  
488 or ADHD PGS as the independent variables. P values and variance explained ( $R^2$ ) were obtained using  
489 R's summary function. Confidence intervals were created using the ci\_rsquared function as part of the  
490 confintr R package (<https://github.com/mayer79/confintr>).

## 491 **Pathway-Based Polygenic Score Analysis**

### 492 **Pathway data**

493 Pathway data for pathway based PGS analysis was sourced from Reactome, an open-source, manually  
494 curated and peer-reviewed pathway database (61). We used all *Homo sapien* pathways that contained  
495 greater than 50 genes, to remove overly specific pathways, and less than 500 genes, to remove overly  
496 broad pathways and limit the computational intensity of pathway-based PGS analysis. This resulted in  
497 451 pathways to test.

### 498 **Pathway-based polygenic score analysis using PRSet**

499 Polygenic score analysis was performed using the tool, PRSet (62). Inputs to PRSet included Reactome  
500 pathway data, published GWAS summary statistics to be used as discovery data, UKB files in PLINK  
501 binary format (.bed, .bim and .fam) to be used as target data and a GTF file for the genome build,  
502 GRCh37. SNPs with a reported  $P > 0.5$  from the corresponding GWAS were removed. This resulted in  
503 final SNP numbers of  $N = 2,374,077$  for the AUT PGS,  $N = 2,187,591$  for the ADHD PGS,  $N =$   
504  $2,525,546$  for the SCZ PGS and  $N = 2,416,496$  for the BP PGS.

505 Pathway-based PGS analysis in PRSet involves three steps. The first step is to map SNPs to genes by  
506 genomic position using GRCh37 start-stop coordinates extended 35kb upstream and 10kb downstream  
507 to include potential regulatory elements. The second step is to perform pathway specific LD clumping  
508 (parameters used: --clump-kb 250kb --clump-p 1 --clump-r2 0.1). Clumping is performed for each  
509 pathway independently to retain the genetic signal for each pathway i.e to prevent a SNP outside of the  
510 pathway being assigned as the lead clumped SNP. The third step involves calculating pathway specific  
511 PGSs for each individual, by summing up, for each SNP, the number of minor alleles at that SNP  
512 multiplied by the GWAS effect size. Finally, performance metrics ( $R^2$  and P value) are calculated for  
513 each pathway. Competitive analysis was performed by creating 5,000 background polygenic scores,  
514 each constructed by randomly sampling the same number of post LD clumped SNPs as contained within  
515 gene-set being tested and conservatively including the gene-set being tested as one background set. A  
516 competitive P value is created using a formula that counts the number of times the P value for a  
517 background gene-set is less than the P value for the gene-set being tested and dividing by the number  
518 of permutations (62). A disadvantage of this method is that the lowest possible P value is  $1 / (\text{number}$   
519  $\text{of permutations} + 1)$ . Therefore, gene-sets that reached the lowest possible competitive P value at 5,000  
520 permutations were re-analysed with a higher number of permutations. Confidence intervals were  
521 calculated for the top performing pathways in R using the same method as for the genome-wide PGSs.

522 Multiple testing correction was performed for pathway-based PGS analysis by calculating a Bonferroni  
523 corrected P value threshold, where 0.05 was divided by the number of tests performed (four GWAS  
524 phenotypes x 451 pathways x 2 UKB phenotypes = 3,608).



525

## 526 **Post-hoc analysis**

### 527 **MAGMA gene-set analysis**

528 Gene-sets that were statistically significant in the PGS analysis, and the genes within them, were tested  
529 for enrichment of common genetic variation using region-based multi-marker analysis of genomic  
530 annotation (MAGMA; <http://ctg.cncr.nl/software/magma>; (63) and summary statistics from published  
531 GWAS on chronotype (69,369 cases and 236,642 controls of British ancestry; 3) and BP. An analysis  
532 involves three steps. First, in the annotation step, SNPs with available GWAS results are mapped on to  
533 genes (GRCh37/hg19 start-stop coordinates +35kb/-10kb). Second, in the gene analysis step, gene P  
534 values are computed for each GWAS dataset. This gene analysis is based on a multiple linear principal  
535 components regression model that accounts for LD between SNPs in each gene, number of SNPs in  
536 each gene, inverse of the mean minor allele count of variants in each gene and the GWAS sample size.  
537 The European panel of the 1000 Genomes data was used as a reference panel for LD. Third, a  
538 competitive GSA based on the gene P values, also using a regression structure, was used to test if the  
539 genes in each gene-set were more strongly associated with either phenotype than other genes in the  
540 genome.

### 541 **eQTL Analysis**

542 Expression quantitative trait loci (eQTL) data was examined using QTLbase2 (27), a database that  
543 aggregates published genome-wide QTL summary statistics across more than 95 tissue and cell types.  
544 We reviewed eQTL data related to genes found within the gene-sets prioritised by pathway-based PGS  
545 analysis. Specifically, we considered genes that achieved significance levels of  $P < 1 \times 10^{-2}$  for BP and  $P$   
546  $< 1 \times 10^{-3}$  for chronotype in the gene-based MAGMA analysis. This was to identify genes individually  
547 enriched for BP and chronotype genetic variation, as these are the genes most likely contributing to the  
548 significant pathway-based PGS results and therefore of interest. Since these genes were already  
549 highlighted as being of interest through pathway-based PGS analysis, it was not necessary that they  
550 were individually statistically significant in the MAGMA analysis.

551 The most statistically significant SNP at each gene locus was searched in QTLbase to identify if it had  
552 been associated with expression changes of the mapped gene in biologically relevant tissues or cell  
553 types, including those related to the brain, central nervous system, peripheral nervous system, blood, or  
554 immune systems. If the top SNP at a locus did not show any eQTL associations, we investigated other  
555 SNPs with similarly low P values at that locus. It was assumed that the SNPs demonstrating the highest  
556 statistical significance for association with BP would also contribute to chronotype prediction, given  
557 that BP effect sizes were used to compute the pathway-based PGSs.

## 558 **Differential Expression Analysis**

559 Differential expression summary data was downloaded as Supplementary Table 1 from Gandal et al.  
560 (2018). This is a PsychENCODE Consortium study that performed RNA-sequencing, followed by  
561 differential expression analysis, of samples isolated from the postmortem dorsolateral prefrontal cortex  
562 samples for 144 BP cases and 899 controls. Specific details of the analysis performed are provided in  
563 the paper (64)

564 More specific methodology details and code for all analyses are provided here:

565 [https://github.com/laurafahey02/Polygenic\\_Score\\_Analyses](https://github.com/laurafahey02/Polygenic_Score_Analyses).

## 566 **Acknowledgements**

567 This project has received funding from the European Research Council (ERC) under the European  
568 Union's Horizon 2020 research and innovation programme (grant agreement No 950010). We would  
569 like to thank Dr Cathy Wyse for discussions related to chronobiology and for reviewing a draft of the  
570 manuscript.

571

## 572 **Bibliography**

- 573 1. Scandurra V, Emberti Gialloreti L, Barbanera F, Scordo MR, Pierini A, Canitano R.  
574 Neurodevelopmental Disorders and Adaptive Functions: A Study of Children With  
575 Autism Spectrum Disorders (ASD) and/or Attention Deficit and Hyperactivity Disorder  
576 (ADHD). *Front Psychiatry*. 2019;10:673.
- 577 2. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental*  
578 *Disorders*. American Psychiatric Association; 2013.
- 579 3. Cohrs S. Sleep Disturbances in Patients with Schizophrenia. *CNS Drugs*.  
580 2008;22(11):939–62.
- 581 4. Cortesi F, Giannotti F, Ivanenko A, Johnson K. Sleep in children with autistic spectrum  
582 disorder. *Sleep Med*. 2010 Aug;11(7):659–64.
- 583 5. Galli J, Loi E, Visconti LM, Mattei P, Eusebi A, Calza S, et al. Sleep Disturbances in  
584 Children Affected by Autism Spectrum Disorder. *Front Psychiatry*. 2022 Feb 17;13.
- 585 6. Wajszilber D, Santisteban JA, Gruber R. Sleep disorders in patients with ADHD: impact  
586 and management challenges. *Nat Sci Sleep*. 2018 Dec;Volume 10:453–80.

- 587 7. Deboer T. Sleep homeostasis and the circadian clock: Do the circadian pacemaker and  
588 the sleep homeostat influence each other's functioning? *Neurobiol Sleep Circadian*  
589 *Rhythms*. 2018 Jun;5:68–77.
- 590 8. Zhang Y, Quiñones GM, Ferrarelli F. Sleep spindle and slow wave abnormalities in  
591 schizophrenia and other psychotic disorders: Recent findings and future directions.  
592 *Schizophr Res*. 2020 Jul;221:29–36.
- 593 9. D'Agostino A, Castelnovo A, Cavallotti S, Casetta C, Marcatili M, Gambini O, et al.  
594 Sleep endophenotypes of schizophrenia: slow waves and sleep spindles in unaffected  
595 first-degree relatives. *NPJ Schizophr*. 2018 Feb 9;4(1):2.
- 596 10. Alachkar A, Lee J, Asthana K, Vakil Monfared R, Chen J, Alhassen S, et al. The hidden  
597 link between circadian entropy and mental health disorders. *Transl Psychiatry*. 2022 Jul  
598 14;12(1):281.
- 599 11. Logan RW, McClung CA. Rhythms of life: circadian disruption and brain disorders  
600 across the lifespan. *Nat Rev Neurosci*. 2019 Jan;20(1):49–65.
- 601 12. Coogan AN, McGowan NM. A systematic review of circadian function, chronotype and  
602 chronotherapy in attention deficit hyperactivity disorder. *ADHD Attention Deficit and*  
603 *Hyperactivity Disorders*. 2017 Sep 7;9(3):129–47.
- 604 13. Bumb JM, Enning F, Mueller JK, van der List T, Rohleder C, Findeisen P, et al.  
605 Differential melatonin alterations in cerebrospinal fluid and serum of patients with major  
606 depressive disorder and bipolar disorder. *Compr Psychiatry*. 2016 Jul;68:34–9.
- 607 14. Brown JP, Martin D, Nagaria Z, Verceles AC, Jobe SL, Wickwire EM. Mental Health  
608 Consequences of Shift Work: An Updated Review. *Curr Psychiatry Rep*. 2020 Feb  
609 18;22(2):7.
- 610 15. von Schantz M, Leocadio-Miguel MA, McCarthy MJ, Papiol S, Landgraf D. Genomic  
611 perspectives on the circadian clock hypothesis of psychiatric disorders. In 2021. p. 153–  
612 91.
- 613 16. von Schantz M. Natural Variation in Human Clocks. In 2017. p. 73–96.
- 614 17. Roenneberg T. How can social jetlag affect health? *Nat Rev Endocrinol*. 2023 Jul  
615 23;19(7):383–4.
- 616 18. Zou H, Zhou H, Yan R, Yao Z, Lu Q. Chronotype, circadian rhythm, and psychiatric  
617 disorders: Recent evidence and potential mechanisms. *Front Neurosci*. 2022;16:811771.

- 618 19. Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-  
619 wide association analyses of chronotype in 697,828 individuals provides insights into  
620 circadian rhythms. *Nat Commun*. 2019 Dec 29;10(1):343.
- 621 20. Mistry S, Harrison JR, Smith DJ, Escott-Price V, Zammit S. The use of polygenic risk  
622 scores to identify phenotypes associated with genetic risk of schizophrenia: Systematic  
623 review. *Schizophr Res*. 2018 Jul;197:2–8.
- 624 21. Ohi K, Ochi R, Noda Y, Wada M, Sugiyama S, Nishi A, et al. Polygenic risk scores for  
625 major psychiatric and neurodevelopmental disorders contribute to sleep disturbance in  
626 childhood: Adolescent Brain Cognitive Development (ABCD) Study. *Transl Psychiatry*.  
627 2021;11(1):187.
- 628 22. Carpena MX, Bonilla C, Matijasevich A, Martins-Silva T, Genro JP, Hutz MH, et al.  
629 Sleep-related traits and attention-deficit/hyperactivity disorder comorbidity: Shared  
630 genetic risk factors, molecular mechanisms, and causal effects. *The World Journal of*  
631 *Biological Psychiatry*. 2021 Nov 26;22(10):778–91.
- 632 23. O’Connell KS, Frei O, Bahrami S, Smeland OB, Bettella F, Cheng W, et al.  
633 Characterizing the Genetic Overlap Between Psychiatric Disorders and Sleep-Related  
634 Phenotypes. *Biol Psychiatry*. 2021 Nov;90(9):621–31.
- 635 24. Zheng Z, Liu S, Sidorenko J, Yengo L, Turley P, Ani A, et al. Leveraging functional  
636 genomic annotations and genome coverage to improve polygenic prediction of complex  
637 traits within and between ancestries. *bioRxiv [Internet]*. 2022 Jan 1;2022.10.12.510418.  
638 Available from: <http://biorxiv.org/content/early/2022/10/14/2022.10.12.510418.abstract>
- 639 25. Choi SW, O’Reilly PF. PRSice-2: Polygenic Risk Score software for biobank-scale data.  
640 *Gigascience*. 2019 Jul 1;8(7).
- 641 26. Ni G, Zeng J, Revez JA, Wang Y, Zheng Z, Ge T, et al. A Comparison of Ten Polygenic  
642 Score Methods for Psychiatric Disorders Applied Across Multiple Cohorts. *Biol*  
643 *Psychiatry*. 2021 Nov 1;90(9):611–20.
- 644 27. Zheng Z, Huang D, Wang J, Zhao K, Zhou Y, Guo Z, et al. QTLbase: an integrative  
645 resource for quantitative trait loci across multiple human molecular phenotypes. *Nucleic*  
646 *Acids Res*. 2020 Jan 8;48(D1):D983–91.
- 647 28. Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The  
648 GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. *Curr*  
649 *Protoc Bioinformatics*. 2016 Jun 20;54:1.30.1-1.30.33.

- 650 29. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.  
651 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*.  
652 2022 Apr 21;604(7906):502–8.
- 653 30. Trubetskoy V, Pardiñas AF, Qi T, Panagiotaropoulou G, Awasthi S, Bigdeli TB, et al.  
654 Mapping genomic loci implicates genes and synaptic biology in schizophrenia. *Nature*.  
655 2022 Apr;604(7906):502–8.
- 656 31. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of  
657 common genetic risk variants for autism spectrum disorder. *Nat Genet*. 2019 Mar  
658 25;51(3):431–44.
- 659 32. Jones SE, Lane JM, Wood AR, van Hees VT, Tyrrell J, Beaumont RN, et al. Genome-  
660 wide association analyses of chronotype in 697,828 individuals provides insights into  
661 circadian rhythms. *Nat Commun*. 2019 Jan 29;10(1):343.
- 662 33. Demontis D, Walters RK, Martin J, Mattheisen M, Als TD, Agerbo E, et al. Discovery of  
663 the first genome-wide significant risk loci for attention deficit/hyperactivity disorder. *Nat*  
664 *Genet*. 2019 Jan 26;51(1):63–75.
- 665 34. Watanabe K, Jansen PR, Savage JE, Nandakumar P, Wang X, Agee M, et al. Genome-  
666 wide meta-analysis of insomnia prioritizes genes associated with metabolic and  
667 psychiatric pathways. *Nat Genet*. 2022 Aug 14;54(8):1125–32.
- 668 35. Mullins N, Forstner AJ, O’Connell KS, Coombes B, Coleman JRI, Qiao Z, et al.  
669 Genome-wide association study of more than 40,000 bipolar disorder cases provides new  
670 insights into the underlying biology. *Nat Genet*. 2021 Jun 17;53(6):817–29.
- 671 36. Bhandari R, Kaur J, Kaur S, Kuhad A. The Nrf2 pathway in psychiatric disorders:  
672 pathophysiological role and potential targeting. *Expert Opin Ther Targets*. 2021 Feb  
673 1;25(2):115–39.
- 674 37. Early JO, Menon D, Wyse CA, Cervantes-Silva MP, Zaslona Z, Carroll RG, et al.  
675 Circadian clock protein BMAL1 regulates IL-1 $\beta$  in macrophages via NRF2. *Proc Natl*  
676 *Acad Sci U S A*. 2018 Sep 4;115(36):E8460–8.
- 677 38. Wible RS, Ramanathan C, Sutter CH, Olesen KM, Kensler TW, Liu AC, et al. NRF2  
678 regulates core and stabilizing circadian clock loops, coupling redox and timekeeping in  
679 *Mus musculus*. *Elife*. 2018 Feb 26;7.


- 680 39. Tamaru T, Hattori M, Ninomiya Y, Kawamura G, Varès G, Honda K, et al. ROS Stress  
681 Resets Circadian Clocks to Coordinate Pro-Survival Signals. *PLoS One*. 2013 Dec  
682 2;8(12):e82006.
- 683 40. Teleanu DM, Niculescu AG, Lungu II, Radu CI, Vladăcenco O, Roza E, et al. An  
684 Overview of Oxidative Stress, Neuroinflammation, and Neurodegenerative Diseases. *Int*  
685 *J Mol Sci*. 2022 May 25;23(11).
- 686 41. Salim S. Oxidative stress and psychological disorders. *Curr Neuropharmacol*. 2014  
687 Mar;12(2):140–7.
- 688 42. Morris G, Walker AJ, Walder K, Berk M, Marx W, Carvalho AF, et al. Increasing Nrf2  
689 Activity as a Treatment Approach in Neuropsychiatry. *Mol Neurobiol*. 2021  
690 May;58(5):2158–82.
- 691 43. Gao W, Guo L, Yang Y, Wang Y, Xia S, Gong H, et al. Dissecting the Crosstalk  
692 Between Nrf2 and NF- $\kappa$ B Response Pathways in Drug-Induced Toxicity. *Front Cell Dev*  
693 *Biol*. 2022 Feb 2;9.
- 694 44. Nakayama T, Okimura K, Shen J, Guh YJ, Tamai TK, Shimada A, et al. Seasonal  
695 changes in NRF2 antioxidant pathway regulates winter depression-like behavior.  
696 *Proceedings of the National Academy of Sciences*. 2020 Apr 28;117(17):9594–603.
- 697 45. Geoffroy PA, Bellivier F, Scott J, Etain B. Seasonality and bipolar disorder: A systematic  
698 review, from admission rates to seasonality of symptoms. *J Affect Disord*. 2014  
699 Oct;168:210–23.
- 700 46. Reynaud E, Berna F, Haffen E, Weiner L, Maruani J, Lejoyeux M, et al. Validity and  
701 Usage of the Seasonal Pattern Assessment Questionnaire (SPAQ) in a French Population  
702 of Patients with Depression, Bipolar Disorders and Controls. *J Clin Med*. 2021 Apr  
703 27;10(9):1897.
- 704 47. Roguski A, Ritter P, Smith DJ. Sensitivity to light in bipolar disorder: implications for  
705 research and clinical practice. *The British Journal of Psychiatry*. 2024 Jan 4;1–4.
- 706 48. Bjorvatn B, Saxvig IW, Waage S, Pallesen S. Self-reported seasonality is strongly  
707 associated with chronotype and weakly associated with latitude. *Chronobiol Int*. 2021  
708 Feb 1;38(2):278–85.
- 709 49. Menculini G, Steardo LJr, Verdolini N, D'Angelo M, Chipi E, Cirimbilli F, et al.  
710 Chronotype is associated with affective temperaments, clinical severity and worse

- 711 treatment outcomes in bipolar disorders: results from a two-center, cross-sectional study.  
712 Int J Psychiatry Clin Pract. 2023 Sep 1;27(3):248–56.
- 713 50. Hashimoto K. Essential Role of Keap1-Nrf2 Signaling in Mood Disorders: Overview and  
714 Future Perspective. Front Pharmacol. 2018;9:1182.
- 715 51. Lukic I, Mitic M, Djordjevic J, Tatalovic N, Bozovic N, Soldatovic I, et al. Lymphocyte  
716 levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of  
717 pro-oxidative state in depressive patients. Neuropsychobiology. 2014;70(1):1–9.
- 718 52. El Marabti E, Malek J, Younis I. Minor Intron Splicing from Basic Science to Disease.  
719 Int J Mol Sci. 2021 Jun 4;22(11):6062.
- 720 53. Olthof AM, Hyatt KC, Kanadia RN. Minor intron splicing revisited: identification of new  
721 minor intron-containing genes and tissue-dependent retention and alternative splicing of  
722 minor introns. BMC Genomics. 2019 Dec 30;20(1):686.
- 723 54. Reber S, Stettler J, Filosa G, Colombo M, Jutzi D, Lenzken SC, et al. Minor intron  
724 splicing is regulated by *FUS* and affected by *ALS*-associated  
725 *FUS* mutants. EMBO J. 2016 Jul 15;35(14):1504–21.
- 726 55. Jangi M, Fleet C, Cullen P, Gupta S V., Mekhoubad S, Chiao E, et al. SMN deficiency in  
727 severe models of spinal muscular atrophy causes widespread intron retention and DNA  
728 damage. Proceedings of the National Academy of Sciences. 2017 Mar 21;114(12).
- 729 56. Buel SM, Debopadhaya S, De los Santos H, Edwards KM, David AM, Dao UH, et al.  
730 The PAICE suite reveals circadian posttranscriptional timing of noncoding RNAs and  
731 spliceosome components in *Mus musculus* macrophages. G3 Genes|Genomes|Genetics.  
732 2022 Aug 25;12(9).
- 733 57. Nasser J, Bergman DT, Fulco CP, Guckelberger P, Doughty BR, Patwardhan TA, et al.  
734 Genome-wide enhancer maps link risk variants to disease genes. Nature. 2021  
735 May;593(7858):238–43.
- 736 58. McCarthy MJ, Gottlieb JF, Gonzalez R, McClung CA, Alloy LB, Cain S, et al.  
737 Neurobiological and behavioral mechanisms of circadian rhythm disruption in bipolar  
738 disorder: A critical multi-disciplinary literature review and agenda for future research  
739 from the ISBD task force on chronobiology. Bipolar Disord. 2022 May 10;24(3):232–63.
- 740 59. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, et al. The UK Biobank  
741 resource with deep phenotyping and genomic data. Nature. 2018 Oct;562(7726):203–9.

- 742 60. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MAR, Bender D, et al. PLINK:  
743 A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses.  
744 The American Journal of Human Genetics. 2007 Sep;81(3):559–75.
- 745 61. Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The  
746 Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018 Jan 4;46(D1):D649–55.
- 747 62. Choi SW, García-González J, Ruan Y, Wu HM, Porras C, Johnson J, et al. PRSet:  
748 Pathway-based polygenic risk score analyses and software. PLoS Genet. 2023  
749 Feb;19(2):e1010624.
- 750 63. de Leeuw CA, Mooij JM, Heskes T, Posthuma D. MAGMA: generalized gene-set  
751 analysis of GWAS data. PLoS Comput Biol. 2015 Apr;11(4):e1004219.
- 752 64. Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-  
753 wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science.  
754 2018 Dec 14;362(6420).
- 755




756



757


758 **Figure 2. Genome-wide polygenic score analysis results.** Linear regressions were run with UK Biobank chronotype or insomnia status as the dependent  
759 variable and SCZ, BP, AUT or ADHD polygenic score as the independent variables. UK Biobank phenotypes were corrected for sex, genotyping batch,  
760 UK Biobank assessment centre and the top ten ancestry-informative genetic principal components prior to running this regression. Horizontal bars show  
761 the variance explained (R<sup>2</sup>), error bars indicate 95% confidence intervals. Bars marked with an asterisk (\*) indicate that they surpass the Bonferroni-  
762 corrected *p* value threshold of  $p \leq 0.0001$ .

763



764

765 **Figure 3. Top performing pathways from pathway-based polygenic score analysis.** Performance metrics for pathway-based polygenic score analysis  
 766 were calculated by regressing insomnia or chronotype case status on each of the pathway-based polygenic scores. Competitive P values were calculated  
 767 by creating at least 5,000 background polygenic scores, consisting of random sets of post-clump SNPs, the same size as the pathway under test (in this  
 768 way, pathway size is controlled for). The competitive P value takes into account the number of times a background gene-set obtains a lower null P value  
 769 than the pathway being tested. The four pathways that resulted in the lowest competitive P values for each of the eight phenotype pairs were identified,  
 770 and their competitive P values across each of the eight phenotype pairs were plotted as a heatmap. The white stars represent pathway based polygenic  
 771 scores statistically significant after multiple testing correction ( $P < 1.39 \times 10^{-5}$ ). Rows are clustered based on similarity.



772

773

774

775

776

**Figure 4. Variance explained (R<sup>2</sup>) by the statistically significant pathway-based BP PGSs, and their subpathways, in predicting chronotype.** Bars marked with an asterisk (\*) indicate that they surpass the Bonferroni-corrected P value threshold of  $P \leq 1.39 \times 10^{-5}$ . A) Total variance explained per pathway. Horizontal bars show the variance explained (R<sup>2</sup>), error bars indicate 95% confidence intervals. B) Average variance explained per SNP. This was obtained by dividing the total variance explained per pathway by the number of SNPs in that pathway.